Table 4:
Author, Year, Country | N | Study Design | Inclusion Criteria | Conditions Tested | NIPT Method, Index Test | Reference Standard(s) | Study Funding |
---|---|---|---|---|---|---|---|
Comparative Studies | |||||||
Bianchi et al, 2014,52 United States | 2,052 | Prospective, comparative | Pregnant people ≥ 18 years old, ≥ 8 weeks’ gestation Exclusion: people who had diagnostic testing within 2 weeks prior to enrolment, or had only NT ultrasound |
Trisomies 21, 18, and 13 | Verifi test, MPSS | Fetal karyotype Neonate examination Birth medical record |
Illumina, Inc. |
Langlois et al, 2017,54 Canada | 1,165 | Prospective, comparative | Pregnant people ≥ 19 years old, singleton pregnancy, < 14 weeks’ gestation | Trisomies 21, 18, and 13 | Harmony test, targeted approach (DANSR) | Fetal karyotype Neonate examination Birth medical record |
Genome Canada, Quebec, British Columbia, and Alberta Quebec ministry Ariosa Diagnostics (arms’ length) |
Norton et al, 2015,56 International | 18,955 | Prospective, comparative | Pregnant people ≥ 18 years old, 10–14 weeks’ gestation Exclusion: people who had a pregnancy loss, or chose to terminate with confirmatory diagnostic testing |
Trisomies 21, 18, and 13, other aneuploidies | Harmony test, targeted approach (DANSR) | Fetal karyotype Neonate examination Birth medical record |
Ariosa Diagnostics Perinatal Quality Foundation |
Quezada et al, 2015,58 United Kingdom | 2,905 | Prospective, comparative | Pregnant people 10–11 weeks’ gestation, singleton pregnancy, who had combined test | Trisomies 21, 18, and 13 | Harmony test, targeted approach (DANSR) | Fetal karyotype | Fetal Medicine Foundation |
Song et al, 2013,59 China | 1,916 | Prospective, comparative | Pregnant people < 35 years old, singleton pregnancies No a priori risk of aneuploidy and undergoing routine prenatal screening |
Trisomies 21, 18, and 13, sex chromosome aneuploidies | Illumina HiSeq platform, MPSS | Fetal karyotype Cord blood Birth medical record |
Chinese National Key Technology Research and Development Program |
Noncomparative Studies | |||||||
del Mar Gil et al, 2014,53 United Kingdom | 207 | Retrospective, noncomparative | Pregnant people without a priori risk, undergoing first-trimester screening, twin pregnancies, 11–13 weeks’ gestation | Trisomies 21, 18, and 13 | Harmony test, targeted approach (DANSR) | Fetal karyotype | Fetal Medicine Foundation Ariosa Diagnostics (provided test and analysis only) |
Nicolaides et al, 2012,55 United Kingdom | 2,230 | Retrospective, noncomparative | Pregnant people 11–13.9 weeks’ gestation, singleton pregnancy, archived sample ≥ 2 mL | Trisomies 21 and 18 | Harmony test, targeted approach (DANSR) | Fetal karyotype Neonate examination |
Fetal Medicine Foundation Ariosa Diagnostics (provided test and analysis only) |
Palomaki et al, 2017,57 United States | 2,691 | Prospective, noncomparative | Pregnant people ≥ 10 weeks’ gestation, satisfy inclusion criteria for Panorama test | Trisomies 21, 18, and 13, monosomy X | Panorama test, targeted approach (single nucleotide polymorphism based) | Fetal karyotype Newborn karyotype and examination |
Natera, Inc. (no involvement) |
Abbreviations: DANSR, Digital Analysis of Selected Regions; MPSS, massively parallel shotgun sequencing; NIPT, noninvasive prenatal testing; NT, nuchal translucency.